Fisetin vs. Dasatinib + Quercetin: Comparing the Two Leading Senolytic Protocols

Senolytics are compounds under active investigation for their ability to selectively eliminate senescent cells—damaged, metabolically active cells that accumulate with age and secrete pro-inflammatory signals known as the senescence-associated secretory phenotype (SASP). As senescent cell burden grows, researchers hypothesize it contributes to tissue dysfunction, chronic inflammation, and age-related disease. Two protocols have emerged as the most discussed in both scientific literature and longevity communities: the combination of dasatinib and quercetin (D+Q) and the flavonoid fisetin used alone.

These protocols differ substantially in their origin, accessibility, evidence base, and risk profile. Dasatinib is an FDA-approved oncology drug combined with the plant flavonoid quercetin, while fisetin is a naturally occurring compound found in strawberries and other fruits that can be purchased as a dietary supplement. Understanding what the current human evidence actually shows—and where it remains limited—is essential before drawing any conclusions about which approach, if any, might be appropriate for a given individual.

What Senescent Cells Are and Why Researchers Want to Clear Them

Cellular senescence is a state in which a cell permanently stops dividing but does not die. While this mechanism originally evolved as a tumor-suppression response, senescent cells that are not efficiently cleared by the immune system accumulate across a lifetime. They continue secreting SASP factors—cytokines, proteases, and growth factors—that can damage neighboring tissue, promote local and systemic inflammation, and potentially accelerate the progression of age-related conditions.

The senolytic hypothesis holds that intermittently and selectively eliminating these cells could reduce their pro-inflammatory burden and slow or partially reverse associated tissue deterioration. In mice, senolytics have extended median and maximum lifespan in several preclinical studies. Whether comparable benefits translate to humans remains an open question that ongoing phase I and early phase II trials are beginning to address.

The Dasatinib + Quercetin Protocol: The Most Extensively Trialed Combination

Dasatinib is a tyrosine kinase inhibitor originally developed to treat certain leukemias. Quercetin is a flavonoid found in onions, apples, and many other plants. Preclinical work identified that the combination targets overlapping but distinct pro-survival pathways in senescent cells, making them more potent together than either agent alone. In human trials, the protocol has typically been administered as short intermittent courses—often a few consecutive days per cycle—rather than as continuous daily dosing, reflecting the hypothesis that senolytics work during a clearance window and do not require chronic use.

A landmark 2019 first-in-human open-label pilot in individuals with idiopathic pulmonary fibrosis (IPF) provided early evidence that oral D+Q could reduce senescent cell markers in adipose tissue and skin biopsies and improve physical function metrics ^[1]. A separate 2019 pilot in people with diabetic kidney disease reported reductions in circulating senescent cell markers and SASP factors following three days of D+Q treatment ^[2]. A 2023 phase I randomized placebo-controlled pilot in IPF extended these findings, evaluating tolerability over a longer course and reporting acceptable short-term safety profiles ^[4].

The D+Q protocol has also been examined in neurological contexts. A 2022 pilot trial known as SToMP-AD explored whether senolytic therapy could modulate Alzheimer’s disease progression, finding that the combination was tolerable in this population and achieving reductions in cerebrospinal fluid senescence markers ^[3]. A 2023 Nature Medicine phase 1 feasibility trial in mild Alzheimer’s disease similarly reported tolerability and provided biomarker data supportive of CNS target engagement ^[5]. A 2024 protocol paper outlines a planned trial extending the D+Q investigation to age-related cognitive decline in individuals with mental health disorders ^[6]. Collectively, these studies establish D+Q as the most clinically trialed senolytic regimen published to date, though they are predominantly feasibility and tolerability studies, not powered efficacy trials.

Fisetin as a Senolytic: Mechanism and Current Evidence Base

Fisetin is a naturally occurring flavonoid most concentrated in strawberries, with smaller amounts in apples, persimmons, grapes, and onions. In cell culture and animal models, fisetin has demonstrated senolytic activity by activating apoptotic pathways—including the caspase cascade—selectively in senescent cells while largely sparing non-senescent cells. A notable mouse study found that fisetin reduced senescent cell burden in aged animals and extended both median and maximum lifespan, generating substantial interest in its potential for human use.

Human clinical investigation of fisetin as a senolytic is at a very early stage. Small trials have examined intermittent high-dose fisetin in the context of frailty in older adults and COVID-19-related outcomes, with tolerability as a primary endpoint. No fisetin-specific clinical trial PMIDs are included in this article’s evidence base because the published human clinical record for fisetin, while emerging, has not yet produced the same volume or breadth of phase I data across multiple disease contexts that the D+Q combination has accumulated.

The proposed dosing strategy for fisetin in longevity communities typically references two-day intermittent courses at doses in the range of 20 mg/kg of body weight—far above normal dietary intake from food and substantially higher than doses used in most supplement research. These doses have not been established as safe or effective in large controlled human trials. As with D+Q, the intermittent approach reflects the same underlying rationale: a short senolytic exposure to clear accumulated senescent cells, followed by a washout period.

How the Two Protocols Compare: Accessibility, Mechanism, and Evidence Depth

The most fundamental practical difference is accessibility. Fisetin is sold as a dietary supplement and can be purchased without a prescription. Dasatinib, by contrast, is a prescription chemotherapy agent, meaning D+Q requires physician involvement and is not available for self-administration outside a clinical or medical context. This distinction shapes how each protocol is pursued in practice: D+Q is administered within clinical trials or under direct medical supervision, while fisetin is frequently used by individuals experimenting independently in longevity contexts.

From a mechanism standpoint, both approaches target senescent cell survival pathways through different molecular entry points. D+Q’s mechanisms include inhibition of BCR-ABL and other tyrosine kinases (dasatinib) and suppression of PI3K/AKT survival signaling alongside flavonoid-associated anti-inflammatory effects (quercetin). Fisetin appears to work partly through Bcl-2 family modulation and caspase activation. The combination’s dual-mechanism approach is thought to broaden senescent cell coverage, though how this translates to clinical outcomes in humans is not yet established.

In terms of published human evidence depth, D+Q holds a clear advantage: multiple phase I trials across diabetic kidney disease ^[2], IPF [PMID 30616998, PMID 36857968], and Alzheimer’s disease [PMID 35098970, PMID 37679434] have been published, collectively suggesting short-course D+Q is tolerable and can reduce circulating and tissue senescence biomarkers. Fisetin lacks this published phase I breadth in the current evidence set, though active trials may change that picture.

Safety Profiles and Who Should Exercise Caution

Dasatinib carries meaningful clinical risks consistent with its classification as a chemotherapy drug. Known adverse effects include pleural effusion, fluid retention, cardiotoxicity, and immunosuppression. Even in the short intermittent courses used in senolytic protocols, it is not a drug to take without a physician’s direct oversight. Its use in senolytic trials occurs under monitored conditions with safety as a primary outcome measure.

Fisetin’s safety profile at dietary intake levels is considered favorable, but the high intermittent doses used in senolytic protocols have not been studied at scale. Fisetin has documented CYP3A4 inhibition activity in laboratory settings and may affect the metabolism of many prescription drugs. It also exhibits antiplatelet properties, creating a theoretical bleeding risk for individuals on anticoagulants or antiplatelet medications. Anyone taking blood thinners or CYP3A4-sensitive medications should consult a physician before attempting high-dose fisetin. Quercetin, used in the D+Q protocol, carries similar considerations around CYP3A4 and anticoagulant interactions.

Neither protocol has a dose or regimen established as safe and effective for general use in healthy aging adults. The trials published to date are phase I feasibility studies in specific disease populations, not general wellness trials in healthy people. Extrapolating these findings to otherwise healthy individuals seeking to slow biological aging introduces additional and unquantified uncertainty.

What Current Evidence Can and Cannot Tell Us

The clinical trials published for D+Q are consistent in demonstrating short-term tolerability and biological target engagement—reductions in senescent cell markers in blood, tissue, and cerebrospinal fluid. What they cannot yet tell us is whether reducing those biomarkers translates to meaningful improvements in lifespan, disease prevention, or functional outcomes in humans. The Alzheimer’s trials [PMID 37679434, PMID 35098970] and the IPF trials [PMID 30616998, PMID 36857968] are explicitly framed as feasibility and tolerability studies; none were powered to detect clinical efficacy.

For fisetin, the preclinical record is compelling by animal-study standards, but the gap between mouse biology and human aging biology is well established. Early human trials have focused on tolerability and safety signals, leaving efficacy questions open. Neither compound has been shown in a controlled human trial to extend lifespan or prevent any specific age-related disease. This is not a reason to dismiss the research—it reflects accurately where the science stands—and larger, longer trials are underway or in planning ^[6].

A Note on the Evidence

Neither fisetin nor the dasatinib + quercetin combination is FDA-approved to treat or prevent any age-related condition, and the intermittent high doses used in senolytic protocols have not been established as safe or effective for general use in healthy adults; individuals on blood thinners, immunosuppressants, or CYP3A4-sensitive medications should consult a physician before use, and dasatinib must only be used under direct medical supervision.

Frequently Asked Questions

What is a senolytic protocol?

A senolytic protocol is a regimen—often administered intermittently rather than daily—designed to selectively eliminate senescent cells, which are aged or damaged cells that accumulate over time and secrete pro-inflammatory factors linked to tissue dysfunction. The two most discussed protocols are fisetin alone and the combination of dasatinib plus quercetin.

Has dasatinib + quercetin been tested in human clinical trials?

Yes. Multiple phase I human trials have been published, including studies in people with idiopathic pulmonary fibrosis [PMID 30616998, PMID 36857968], diabetic kidney disease ^[2], and Alzheimer’s disease [PMID 35098970, PMID 37679434]. These trials primarily assessed safety and tolerability; they were not designed or powered to measure long-term efficacy.

Is fisetin as well-studied as dasatinib + quercetin in humans?

Based on the published evidence available, no. D+Q has been evaluated across several phase I human trials in multiple disease populations, while published fisetin human trial data are more limited. Preclinical animal evidence for fisetin as a senolytic is robust, but the human clinical record is still in earlier stages compared to D+Q.

Why are senolytic protocols taken intermittently rather than every day?

The intermittent dosing strategy reflects the proposed senolytic mechanism: these compounds are hypothesized to clear senescent cells during a short exposure window, after which continued exposure is not needed until a new burden of senescent cells accumulates. Intermittent dosing also limits cumulative drug exposure, which is particularly relevant for dasatinib given its known side-effect profile.

Can I take fisetin as a supplement without a doctor?

Fisetin is sold as a dietary supplement and does not require a prescription. However, the high intermittent doses used in senolytic protocols are far above typical supplement doses and have not been established as safe in large controlled trials. People on blood thinners or medications metabolized by CYP3A4 enzymes should consult a physician before use. This article is informational, not medical advice.

Do these senolytics cure aging or age-related diseases?

No. Neither fisetin nor the dasatinib + quercetin combination is FDA-approved to treat, cure, or prevent any age-related condition. Published human trials are early-phase feasibility studies that demonstrate tolerability and reductions in senescence biomarkers [PMID 37679434, PMID 31542391], but they do not establish that either protocol extends human lifespan or prevents disease.

References

1. Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine (2019). PMID 30616998
2. Hickson LJ et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine (2019). PMID 31542391
3. Gonzales MM et al. Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial. The journal of prevention of Alzheimer's disease (2022). PMID 35098970
4. Nambiar A et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine (2023). PMID 36857968
5. Gonzales MM et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature medicine (2023). PMID 37679434
6. Schweiger A et al. Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Research (2024). PMID 40443429

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.